SUNPHARMA — Sun Pharmaceutical Industries Share News
0.000.00%
- IN₹4.51tn
- IN₹4.19tn
- IN₹584.62bn
Organon jumps on report of $12 billion buyout bid
Organon jumps on report of $12 bln buyout bid
India's Sun Pharma set for worst day in nearly 6 years on report of $12 bln Organon bid
Indian pharma shares extend losses on US tariffs; brokerages see limited impact
India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation
Indian pharma stocks fall on report of Trump's new tariffs on select drugmakers
India's Sun Pharma logs second-straight month of gains
Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
India's hospitals, drugmakers set for weekly gains on steady earnings outlook, GLP-1 scope
UBS initiates Indian pharma coverage amid weight-loss drug opportunity
India drug regulator tightens surveillance against unauthorised weight-loss drug sales (updated)
Factbox: Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy
Analysts upbeat on semaglutide opportunity as patent expiry triggers India generics
Brief: Sun Pharma Launches Its Semaglutide Injection Under Brand Names, Noveltreat And Sematrinity In India
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
Brief: Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis
Brief: Sun Pharma - Us FDA Accepts SBLA For Ilumya For Active Psoriatic Arthritis
Biocon aims for revenue surge with rollout of generic weight-loss drugs
Biocon aims for revenue surge with rollout of generic weight-loss drugs